WIN 64338

Drug Profile

WIN 64338

Latest Information Update: 06 Aug 2002

Price : $50

At a glance

  • Originator Sanofi Winthrop
  • Class Analgesics; Antiasthmatics; Muscle relaxants; Naphthalenes; Organophosphorus compounds
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
  • 23 Jul 1998 An in vitro study has been added to the pharmacodynamics section
  • 08 Nov 1995 An in vivo study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top